Paris, September 1, 2009 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialised in protein interactions, today announces the signature of a 3-year research services agreement worth USD 2.1 million with an US multinational life sciences company.
Under the agreement, Hybrigenics will build specific cDNA libraries from the living organisms of interest to the client company, perform yeast two-hybrid (Y2H) screens on demand, and compile exclusive bioinformatics databases of newly identified protein interactions. The results will be visualized and exploited with Hybrigenics' highly sophisticated bioinformatics tools, such as its PIM-Rider software. As part of this 3-year commitment of USD 700,000 per year, Hybrigenics will designate dedicated program managers and ensure top priority completion of the Y2H screens requested by the client company.
"This contract shows that, in addition to its unique expertise and technology, Hybrigenics can also offer well-designed externalization contract conditions that can convince major life sciences organizations to work with Hybrigenics for reasons of speed, efficiency and cost-effectiveness against the background of the current economic environment that is driving rationalization," said Remi Delansorne, Hybrigenics' CEO.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, is the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
Hybrigenics is also focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.
Under the agreement, Hybrigenics will build specific cDNA libraries from the living organisms of interest to the client company, perform yeast two-hybrid (Y2H) screens on demand, and compile exclusive bioinformatics databases of newly identified protein interactions. The results will be visualized and exploited with Hybrigenics' highly sophisticated bioinformatics tools, such as its PIM-Rider software. As part of this 3-year commitment of USD 700,000 per year, Hybrigenics will designate dedicated program managers and ensure top priority completion of the Y2H screens requested by the client company.
"This contract shows that, in addition to its unique expertise and technology, Hybrigenics can also offer well-designed externalization contract conditions that can convince major life sciences organizations to work with Hybrigenics for reasons of speed, efficiency and cost-effectiveness against the background of the current economic environment that is driving rationalization," said Remi Delansorne, Hybrigenics' CEO.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, is the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
Hybrigenics is also focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.
